Zhaohui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhaohui Wang has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Shuai Lu
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
15 shared publicationsJing Hu
12 shared publicationsWenhu Liu
10 shared publicationsYa Wang
10 shared publicationsQian Xu
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
8 shared publications- Yan Wang
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98
HnRNPK suppresses macrophage-driven inflammation in autoimmune myocarditis by restraining NCF1-dependent oxidized phospholipid signaling and ferroptosis-related changes
- 8 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98
Open AccessHnRNPK suppresses macrophage-driven inflammation in autoimmune myocarditis by restraining NCF1-dependent oxidized phospholipid signaling and ferroptosis-related changes
- Open Access
- 23 August 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 958
Long-Term Air Pollution Exposure, Cardiovascular Disease, and Cardiometabolic Risk Factors in Middle-Aged and Older Chinese Adults: A Prospective Cohort Study
The substantial burden of cardiovascular disease (CVD) attributable to air pollution remains a critical public health challenge, yet its combined effect with cardiometabolic factors is not fully understood. This study leveraged data from the Global Burden of Disease Study (GBD) and the China High Air Pollutants (CHAP) database to evaluate the CVD burden attributable to air pollution, which was found to increase progressively with age. We conducted a cross-sectional analysis using baseline (2011) data from 7420 participants aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS), and a prospective cohort analysis in 8792 participants followed through 2020. In the longitudinal analysis, long-term exposure to PM2.5 (HR = 1.09, 95% CI: 1.03–1.16) and PM10 (HR = 1.07, 95% CI: 1.04–1.10) was significantly associated with an elevated risk of incident CVD, whereas the association for NO2 was nominally significant (HR = 1.12, 95% CI: 1.00–1.24) and that for O3 was not statistically significant (HR = 1.08, 95% CI: 0.93–1.27). Furthermore, prolonged exposure to these pollutants was associated with a higher prevalence of hypertension, diabetes, dyslipidemia, and obesity, and with adverse levels of metabolic indicators, including the TyG, TyG-BMI, and TyG-WC indices. A random forest model showed modest discrimination for incident CVD (AUC = 0.656), identifying PM10 and PM2.5 as the most important predictors. In conclusion, long-term exposure to ambient air pollution, particularly particulate matter, is associated with an increased risk of CVD and cardiometabolic disorders in middle-aged and older Chinese adults.
- 23 August 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 958
Open AccessLong-Term Air Pollution Exposure, Cardiovascular Disease, and Cardiometabolic Risk Factors in Middle-Aged and Older Chinese Adults: A Prospective Cohort Study
The substantial burden of cardiovascular disease (CVD) attributable to air pollution remains a critical public health challenge, yet its combined effect with cardiometabolic factors is not fully understood. This study leveraged data from the Global Burden of Disease Study (GBD) and the China High Air Pollutants (CHAP) database to evaluate the CVD burden attributable to air pollution, which was found to increase progressively with age. We conducted a cross-sectional analysis using baseline (2011) data from 7420 participants aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS), and a prospective cohort analysis in 8792 participants followed through 2020. In the longitudinal analysis, long-term exposure to PM2.5 (HR = 1.09, 95% CI: 1.03–1.16) and PM10 (HR = 1.07, 95% CI: 1.04–1.10) was significantly associated with an elevated risk of incident CVD, whereas the association for NO2 was nominally significant (HR = 1.12, 95% CI: 1.00–1.24) and that for O3 was not statistically significant (HR = 1.08, 95% CI: 0.93–1.27). Furthermore, prolonged exposure to these pollutants was associated with a higher prevalence of hypertension, diabetes, dyslipidemia, and obesity, and with adverse levels of metabolic indicators, including the TyG, TyG-BMI, and TyG-WC indices. A random forest model showed modest discrimination for incident CVD (AUC = 0.656), identifying PM10 and PM2.5 as the most important predictors. In conclusion, long-term exposure to ambient air pollution, particularly particulate matter, is associated with an increased risk of CVD and cardiometabolic disorders in middle-aged and older Chinese adults.
- Open Access
- 27 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6706
Intestinal Flora and Myocarditis: Potential Mechanisms and Therapeutic Strategies Affecting Disease Progression and Cardiac Function
Myocarditis is a clinically challenging form of inflammatory heart disease with heterogeneous etiologies, limited diagnostic tools, no targeted therapies, and a substantial risk of progression to heart failure or sudden cardiac death, particularly in young adults. Emerging evidence has increasingly associated myocarditis with gut microbiota dysbiosis. This review explores the gut–myocarditis axis, highlighting key mechanisms and therapeutic strategies. Significant alterations in gut microbial composition are observed in myocarditis patients and animal models. Gut microbiota influences disease development through multiple pathways: compromised intestinal barrier integrity leading to bacterial translocation and systemic inflammation via MAMP/PRR signaling (e.g., TLRs, NLRs); production of metabolites—including pro-inflammatory trimethylamine N-oxide (TMAO), anti-inflammatory short-chain fatty acids (SCFAs), and immunomodulatory bile acids—that regulate host inflammatory responses, immune cell differentiation, oxidative stress, and fibrotic remodeling; and molecular mimicry, where microbial peptides (e.g., from Bacteroides thetaiotaomicron) trigger cross-reactive autoimmune responses against cardiac proteins. Regarding therapeutic strategies, this review discusses fecal microbiota transplantation (FMT), probiotics, prebiotics, dietary modulation, and emerging approaches including engineered bacteria and oral nanomedicines. Although these strategies hold promise, their efficacy and safety remain to be validated in large-scale clinical trials, and further investigation is warranted.
- 27 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6706
Open AccessIntestinal Flora and Myocarditis: Potential Mechanisms and Therapeutic Strategies Affecting Disease Progression and Cardiac Function
Myocarditis is a clinically challenging form of inflammatory heart disease with heterogeneous etiologies, limited diagnostic tools, no targeted therapies, and a substantial risk of progression to heart failure or sudden cardiac death, particularly in young adults. Emerging evidence has increasingly associated myocarditis with gut microbiota dysbiosis. This review explores the gut–myocarditis axis, highlighting key mechanisms and therapeutic strategies. Significant alterations in gut microbial composition are observed in myocarditis patients and animal models. Gut microbiota influences disease development through multiple pathways: compromised intestinal barrier integrity leading to bacterial translocation and systemic inflammation via MAMP/PRR signaling (e.g., TLRs, NLRs); production of metabolites—including pro-inflammatory trimethylamine N-oxide (TMAO), anti-inflammatory short-chain fatty acids (SCFAs), and immunomodulatory bile acids—that regulate host inflammatory responses, immune cell differentiation, oxidative stress, and fibrotic remodeling; and molecular mimicry, where microbial peptides (e.g., from Bacteroides thetaiotaomicron) trigger cross-reactive autoimmune responses against cardiac proteins. Regarding therapeutic strategies, this review discusses fecal microbiota transplantation (FMT), probiotics, prebiotics, dietary modulation, and emerging approaches including engineered bacteria and oral nanomedicines. Although these strategies hold promise, their efficacy and safety remain to be validated in large-scale clinical trials, and further investigation is warranted.
- Top Cited PapersOpen Access
- 16 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 201
The Role of the NF-κB Signaling Pathway in Atherosclerotic Plaque Rupture and Targeted Therapeutic Strategies
Atherosclerosis (AS) is a disease characterized by chronic vascular wall inflammation and lipid deposition. Although lipid-lowering drugs such as statins have significantly reduced cardiovascular event rates, “residual inflammatory risk” remains a key factor driving disease progression and plaque rupture. As a central regulator of the inflammatory response, the nuclear factor-κappaB (NF-κB) signaling network comprises both canonical pro-inflammatory pathways and functionally more complex non-canonical pathways. Increasing evidence in recent years indicates that abnormal and sustained activation of the non-canonical NF-κB signaling pathway plays a pivotal role in driving plaque rupture. This review first elaborates on the shift in AS strategies from “lipid-lowering” to “anti-inflammatory” approaches, followed by an in-depth analysis of the molecular activation mechanisms of the NF-κB signaling pathway and its distinctiveness in the AS pathological process, along with its epigenetic regulation. It emphasizes how this pathway drives pathological angiogenesis and regulates vascular smooth muscle cell (VSMC) phenotypic switching and macrophage function, thereby forming a vicious cycle that amplifies inflammation and structural damage, ultimately leading to acute cardiovascular events. Finally, we systematically summarize current progress and challenges in drug development targeting the NF-κB pathway (e.g., targeting key kinases like NIK and IKKα), aiming to provide theoretical foundations and future directions for novel therapeutic strategies to stabilize coronary plaques and prevent acute coronary syndromes.
- 16 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 201
Top Cited PapersOpen AccessThe Role of the NF-κB Signaling Pathway in Atherosclerotic Plaque Rupture and Targeted Therapeutic Strategies
Atherosclerosis (AS) is a disease characterized by chronic vascular wall inflammation and lipid deposition. Although lipid-lowering drugs such as statins have significantly reduced cardiovascular event rates, “residual inflammatory risk” remains a key factor driving disease progression and plaque rupture. As a central regulator of the inflammatory response, the nuclear factor-κappaB (NF-κB) signaling network comprises both canonical pro-inflammatory pathways and functionally more complex non-canonical pathways. Increasing evidence in recent years indicates that abnormal and sustained activation of the non-canonical NF-κB signaling pathway plays a pivotal role in driving plaque rupture. This review first elaborates on the shift in AS strategies from “lipid-lowering” to “anti-inflammatory” approaches, followed by an in-depth analysis of the molecular activation mechanisms of the NF-κB signaling pathway and its distinctiveness in the AS pathological process, along with its epigenetic regulation. It emphasizes how this pathway drives pathological angiogenesis and regulates vascular smooth muscle cell (VSMC) phenotypic switching and macrophage function, thereby forming a vicious cycle that amplifies inflammation and structural damage, ultimately leading to acute cardiovascular events. Finally, we systematically summarize current progress and challenges in drug development targeting the NF-κB pathway (e.g., targeting key kinases like NIK and IKKα), aiming to provide theoretical foundations and future directions for novel therapeutic strategies to stabilize coronary plaques and prevent acute coronary syndromes.
- Open Access
- 30 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 58
Optimizing Extracellular Vesicles for Cardiac Repair Post-Myocardial Infarction: Approaches and Challenges
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.
- 30 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 16 (1) , 58
Open AccessOptimizing Extracellular Vesicles for Cardiac Repair Post-Myocardial Infarction: Approaches and Challenges
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.
- Open Access
- 19 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1268
HCTG-Net: A Hybrid CNN–Transformer Network with Gated Fusion for Automatic ECG Arrhythmia Diagnosis
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.
- 19 November 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1268
Open AccessHCTG-Net: A Hybrid CNN–Transformer Network with Gated Fusion for Automatic ECG Arrhythmia Diagnosis
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.
- Open Access
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1714726
Case Report: Syphilitic proximal coronary stenosis with discordant serology: diagnostic validation by optical coherence tomography
Cardiovascular syphilis, a late manifestation of Treponema pallidum infection, remains a diagnostic challenge, particularly when serological tests are discordant. We report a case of a 70-year-old male with recurrent chest tightness and discordant syphilis serology (non-reactive RPR, reactive TPPA). Coronary angiography revealed a critical stenosis at the distal left main coronary artery, specifically involving the ostio-proximal segment of the left anterior descending (LAD) artery. Critically, the absence of systemic atherosclerosis was evidenced by a coronary artery calcium score of zero and normal carotid intima-media thickness. Optical coherence tomography (OCT) provided definitive diagnostic clarity by revealing microstructural features pathognomonic for syphilitic vasculitis: vasa vasorum obliteration, elastic lamina fragmentation, and adventitial fibrosis with microcalcifications. These findings were distinct from atherosclerotic plaque. The patient successfully underwent OCT-guided percutaneous coronary intervention followed by targeted antibiotic therapy. This case highlights the indispensable role of OCT in establishing the etiology of non-atherosclerotic proximal coronary stenosis, underscoring that cardiovascular syphilis must be considered even with non-reactive non-treponemal tests in late-stage disease.
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1714726
Open AccessCase Report: Syphilitic proximal coronary stenosis with discordant serology: diagnostic validation by optical coherence tomography
Cardiovascular syphilis, a late manifestation of Treponema pallidum infection, remains a diagnostic challenge, particularly when serological tests are discordant. We report a case of a 70-year-old male with recurrent chest tightness and discordant syphilis serology (non-reactive RPR, reactive TPPA). Coronary angiography revealed a critical stenosis at the distal left main coronary artery, specifically involving the ostio-proximal segment of the left anterior descending (LAD) artery. Critically, the absence of systemic atherosclerosis was evidenced by a coronary artery calcium score of zero and normal carotid intima-media thickness. Optical coherence tomography (OCT) provided definitive diagnostic clarity by revealing microstructural features pathognomonic for syphilitic vasculitis: vasa vasorum obliteration, elastic lamina fragmentation, and adventitial fibrosis with microcalcifications. These findings were distinct from atherosclerotic plaque. The patient successfully underwent OCT-guided percutaneous coronary intervention followed by targeted antibiotic therapy. This case highlights the indispensable role of OCT in establishing the etiology of non-atherosclerotic proximal coronary stenosis, underscoring that cardiovascular syphilis must be considered even with non-reactive non-treponemal tests in late-stage disease.
- Open Access
- 22 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334914
Sex difference in the burden of rheumatic heart disease: Insights from the Global Burden of Disease Study 2021
Introduction: Rheumatic heart disease (RHD) shows significant sex differences in disease burden. This study assesses these differences using data from the Global Burden of Disease Study 2021 (GBD 2021). Methods: We extracted sex-specific indicators for RHD from the GBD database, including disability-adjusted life years (DALYs), mortality, and prevalence. Trends were analyzed using estimated annual percentage change (EAPC), and sex differences were assessed via female-by-male ratios. Results: From 1990 to 2021, females consistently had higher age-standardized DALYs (ASDR), mortality (ASMR), and prevalence rates (ASPR) than males. These differences were particularly pronounced in specific regions and age groups. In 2021, female ASDR and ASMR in Andorra were over three times higher than males, while in the Cook Islands, they were less than half of males’ rates. In the United States Virgin Islands, females aged 10–19 had an ASMR only 0.01 times that of males, whereas in the United Arab Emirates, females aged 70–89 had ASDR and ASMR five times higher than males. Overall, the female-by-male ratios in ASDR, ASMR, and ASPR have shown a yearly decline. However, these ratios are positively correlated with the Sociodemographic Index (SDI), with correlation coefficients of 0.1 for ASDR, 0.22 for ASMR, and 0.47 for ASPR. Conclusion: Our study reveals a persistent global sex disparity in RHD burden from 1990 to 2021, with females generally experiencing a heavier burden. These findings underscore the need for sex-specific approaches in RHD prevention and treatment and further research into the underlying factors driving these disparities.
- 22 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334914
Open AccessSex difference in the burden of rheumatic heart disease: Insights from the Global Burden of Disease Study 2021
Introduction: Rheumatic heart disease (RHD) shows significant sex differences in disease burden. This study assesses these differences using data from the Global Burden of Disease Study 2021 (GBD 2021). Methods: We extracted sex-specific indicators for RHD from the GBD database, including disability-adjusted life years (DALYs), mortality, and prevalence. Trends were analyzed using estimated annual percentage change (EAPC), and sex differences were assessed via female-by-male ratios. Results: From 1990 to 2021, females consistently had higher age-standardized DALYs (ASDR), mortality (ASMR), and prevalence rates (ASPR) than males. These differences were particularly pronounced in specific regions and age groups. In 2021, female ASDR and ASMR in Andorra were over three times higher than males, while in the Cook Islands, they were less than half of males’ rates. In the United States Virgin Islands, females aged 10–19 had an ASMR only 0.01 times that of males, whereas in the United Arab Emirates, females aged 70–89 had ASDR and ASMR five times higher than males. Overall, the female-by-male ratios in ASDR, ASMR, and ASPR have shown a yearly decline. However, these ratios are positively correlated with the Sociodemographic Index (SDI), with correlation coefficients of 0.1 for ASDR, 0.22 for ASMR, and 0.47 for ASPR. Conclusion: Our study reveals a persistent global sex disparity in RHD burden from 1990 to 2021, with females generally experiencing a heavier burden. These findings underscore the need for sex-specific approaches in RHD prevention and treatment and further research into the underlying factors driving these disparities.
- 16 September 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (11) , 4577-4589
Identification of shared diagnostic biomarkers and potential co-morbidity mechanisms between primary Sjogren’s syndrome and chronic kidney disease
Background The mechanisms linking primary Sjogren’s syndrome (pSS) to chronic kidney disease (CKD) are obscure. Our study sought to uncover shared genetic connections and pathways between these conditions. Methods Datasets for pSS and CKD were sourced from GEO. WGCNA alongside differential expression assessment was employed to pinpoint common genes. GO and KEGG were applied for gene enrichment. Key genes were selected using LASSO, Random Forest, and SVM-RFE. Clinical prediction models were constructed using multi-factor logistic regression. GSEA and immune infiltration analyses explored the mechanisms linking key genes in pSS and CKD. MR analysis and SMR approach assessed the genetic link between pSS and CKD, evaluating the impact of co-shared genes on these conditions. Result We identified 104 common genes using WGCNA and differential expression analysis. GO and KEGG analyses hinted at cancer involvement in both diseases. Machine learning models pinpointed five genes as strong diagnostic biomarkers for both pSS and CKD, with NUDT1 and COMMD2 validated in independent cohorts. Clinical prediction models were constructed based on these two genes. GSEA and immune infiltration analysis suggested immune processes, particularly T cell infiltration, were implicated in both diseases. Bidirectional MR analysis failed to establish a causal link between the two diseases, yet SMR analysis revealed associations between NUDT1 and COMMD2 expression and the development of pSS and CKD. Conclusion This study uncovered crucial genes shared between pSS and CKD, shedding light on their co-morbidity mechanisms and possible diagnostic biomarkers. Key Points • This study unveils for the first time the immunological association between PSS and CKD. • NUDT1 and COMMD2 are identified as key molecules in the comorbidity mechanism of PSS and CKD. • A diagnostic model for the comorbidity of PSS and CKD is constructed.
- 16 September 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (11) , 4577-4589
Identification of shared diagnostic biomarkers and potential co-morbidity mechanisms between primary Sjogren’s syndrome and chronic kidney disease
Background The mechanisms linking primary Sjogren’s syndrome (pSS) to chronic kidney disease (CKD) are obscure. Our study sought to uncover shared genetic connections and pathways between these conditions. Methods Datasets for pSS and CKD were sourced from GEO. WGCNA alongside differential expression assessment was employed to pinpoint common genes. GO and KEGG were applied for gene enrichment. Key genes were selected using LASSO, Random Forest, and SVM-RFE. Clinical prediction models were constructed using multi-factor logistic regression. GSEA and immune infiltration analyses explored the mechanisms linking key genes in pSS and CKD. MR analysis and SMR approach assessed the genetic link between pSS and CKD, evaluating the impact of co-shared genes on these conditions. Result We identified 104 common genes using WGCNA and differential expression analysis. GO and KEGG analyses hinted at cancer involvement in both diseases. Machine learning models pinpointed five genes as strong diagnostic biomarkers for both pSS and CKD, with NUDT1 and COMMD2 validated in independent cohorts. Clinical prediction models were constructed based on these two genes. GSEA and immune infiltration analysis suggested immune processes, particularly T cell infiltration, were implicated in both diseases. Bidirectional MR analysis failed to establish a causal link between the two diseases, yet SMR analysis revealed associations between NUDT1 and COMMD2 expression and the development of pSS and CKD. Conclusion This study uncovered crucial genes shared between pSS and CKD, shedding light on their co-morbidity mechanisms and possible diagnostic biomarkers. Key Points • This study unveils for the first time the immunological association between PSS and CKD. • NUDT1 and COMMD2 are identified as key molecules in the comorbidity mechanism of PSS and CKD. • A diagnostic model for the comorbidity of PSS and CKD is constructed.
- Open Access
- 30 August 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (8)
Exploring optimal serum selenium range for heart failure prevention: A U-shaped association and mediation by hepatic steatosis in US adults
Objective: The relationship between serum selenium levels and heart failure risk remains unclear. This study aimed to investigate the potential nonlinear association between serum selenium level and heart failure risk and explore whether hepatic steatosis and dyslipidemia mediate this relationship. Methods: Data from 6969 adults in the National Health and Nutrition Examination Survey 2017–2020 cohort were analyzed. Logistic regression, restricted cubic spline, and random forest models were used to assess associations between serum selenium level and heart failure risk. Mediation analysis was used to evaluate the indirect effects of hepatic steatosis and lipid parameters. Mendelian randomization was used to infer causality. Results: A U-shaped association was identified between serum selenium level and heart failure risk ( P for nonlinearity = 0.003), with the lowest risk observed at 150–160 µg/L. Both low and high selenium levels were associated with increased heart failure risk. Hepatic steatosis and lipid markers partially mediated this association. Mendelian randomization analysis suggested a potential causal effect of genetically predicted serum selenium level on heart failure risk. Conclusion: These findings highlight a nonlinear association between selenium exposure and heart failure and suggest possible metabolic pathways underlying this association. However, further research is needed before any clinical recommendations can be made.
- 30 August 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (8)
Open AccessExploring optimal serum selenium range for heart failure prevention: A U-shaped association and mediation by hepatic steatosis in US adults
Objective: The relationship between serum selenium levels and heart failure risk remains unclear. This study aimed to investigate the potential nonlinear association between serum selenium level and heart failure risk and explore whether hepatic steatosis and dyslipidemia mediate this relationship. Methods: Data from 6969 adults in the National Health and Nutrition Examination Survey 2017–2020 cohort were analyzed. Logistic regression, restricted cubic spline, and random forest models were used to assess associations between serum selenium level and heart failure risk. Mediation analysis was used to evaluate the indirect effects of hepatic steatosis and lipid parameters. Mendelian randomization was used to infer causality. Results: A U-shaped association was identified between serum selenium level and heart failure risk ( P for nonlinearity = 0.003), with the lowest risk observed at 150–160 µg/L. Both low and high selenium levels were associated with increased heart failure risk. Hepatic steatosis and lipid markers partially mediated this association. Mendelian randomization analysis suggested a potential causal effect of genetically predicted serum selenium level on heart failure risk. Conclusion: These findings highlight a nonlinear association between selenium exposure and heart failure and suggest possible metabolic pathways underlying this association. However, further research is needed before any clinical recommendations can be made.